Veracyte (VCYT) Financials

$38.90 +0.65 (+1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$38.87 -0.03 (-0.08%)

As of 04:10 PM Eastern

Annual Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-34	-31	-31	-23	-13	-35	-76	-37	-74	24	66
Consolidated Net Income / (Loss)	-34	-31	-31	-23	-13	-35	-76	-37	-74	24	66
Net Income / (Loss) Continuing Operations	-34	-31	-31	-23	-13	-35	-76	-37	-74	24	66
Total Pre-Tax Income	-34	-32	-31	-23	-13	-35	-82	-36	-77	26	68
Total Operating Income	-33	-29	-27	-22	-15	-35	-82	-41	-86	16	58
Total Gross Profit	28	40	44	59	84	76	145	176	230	298	363
Total Revenue	50	65	72	92	120	117	220	297	361	446	517
Operating Revenue	50	65	72	92	120	117	220	297	361	446	517
Total Cost of Revenue	21	25	28	33	37	41	74	121	131	148	155
Operating Cost of Revenue	21	25	28	33	37	41	74	102	113	136	144
Total Operating Expenses	61	68	70	81	99	111	227	236	334	294	315
Selling, General & Admin Expense	23	24	23	24	29	37	101	73	86	111	111
Marketing Expense	25	28	32	41	54	52	80	98	101	95	100
Research & Development Expense	13	15	14	15	15	17	30	41	57	69	71
Amortization Expense	0.80	1.07	1.07	1.07	1.40	5.10	16	21	21	15	13
Impairment Charge	-	-	-	-	-	-	0.00	3.32	68	3.37	21
Total Other Income / (Expense), net	-0.38	-2.76	-4.94	-0.77	2.53	0.48	0.25	4.65	9.18	9.60	10
Other Income / (Expense), net	-	-	-	1.20	2.53	0.48	0.25	4.65	9.18	9.60	10
Income Tax Expense	-	-	-	-	0.00	0.00	-6.09	0.13	-2.21	1.61	1.85
Basic Earnings per Share	($1.30)	($1.09)	($0.91)	($0.62)	($0.27)	($0.66)	($1.11)	($0.51)	($1.02)	$0.32	$0.84
Weighted Average Basic Shares Outstanding	25.99M	28.83M	33.93M	37.02M	46.14M	53.24M	67.89M	71.55M	72.64M	76.48M	78.58M
Diluted Earnings per Share	($1.30)	($1.09)	($0.91)	($0.62)	($0.27)	($0.66)	($1.11)	($0.51)	($1.02)	$0.31	$0.82
Weighted Average Diluted Shares Outstanding	25.99M	28.83M	33.93M	37.02M	46.14M	53.24M	67.89M	71.55M	72.64M	78.16M	80.57M
Weighted Average Basic & Diluted Shares Outstanding	25.99M	28.83M	33.93M	37.02M	46.14M	53.24M	71.22M	72.15M	75.07M	77.94M	79.46M

This table shows Veracyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-30	-28	-1.86	5.73	15	5.11	7.05	-0.98	19	41	29
Consolidated Net Income / (Loss)	-30	-28	-1.86	5.73	15	5.11	7.05	-0.98	19	41	29
Net Income / (Loss) Continuing Operations	-30	-28	-1.86	5.73	15	5.11	7.05	-0.98	19	41	29
Total Pre-Tax Income	-30	-30	-1.91	7.36	17	3.44	7.43	1.25	19	41	30
Total Operating Income	-32	-36	-4.66	4.61	12	4.18	2.90	-5.27	23	37	23
Total Gross Profit	58	60	62	78	79	76	80	90	91	102	101
Total Revenue	90	98	97	114	116	119	114	130	132	141	139
Operating Revenue	90	98	97	114	116	119	114	130	132	141	139
Total Cost of Revenue	32	38	34	37	37	43	35	40	41	39	38
Operating Cost of Revenue	28	29	31	34	34	37	32	38	38	36	35
Total Operating Expenses	94	104	70	76	70	77	79	98	71	67	81
Selling, General & Admin Expense	16	24	26	32	26	27	34	32	27	17	24
Marketing Expense	24	25	24	24	23	25	24	25	24	26	27
Research & Development Expense	13	19	16	16	18	19	18	16	16	21	27
Amortization Expense	5.34	4.56	3.65	3.79	3.80	3.61	3.21	3.29	3.33	3.33	3.29
Total Other Income / (Expense), net	1.97	5.04	2.75	2.76	4.83	-0.73	4.52	6.52	-4.06	3.44	7.33
Other Income / (Expense), net	1.97	5.04	2.75	2.76	4.83	-0.73	4.52	6.52	-4.06	3.44	7.33
Income Tax Expense	-0.15	-2.18	-0.04	1.63	1.69	-1.67	0.38	2.23	-0.25	-0.52	1.27
Basic Earnings per Share	($0.41)	($0.38)	($0.02)	$0.07	$0.20	$0.07	$0.09	($0.01)	$0.24	$0.52	$0.36
Weighted Average Basic Shares Outstanding	72.80M	72.64M	74.76M	76.54M	77.01M	76.48M	78.03M	78.39M	78.73M	78.58M	79.54M
Diluted Earnings per Share	($0.41)	($0.38)	($0.02)	$0.07	$0.19	$0.07	$0.09	($0.01)	$0.24	$0.50	$0.35
Weighted Average Diluted Shares Outstanding	72.80M	72.64M	74.76M	77.16M	78.46M	78.16M	80.06M	78.39M	79.69M	80.57M	81.31M
Weighted Average Basic & Diluted Shares Outstanding	73.04M	75.07M	76.45M	76.81M	77.50M	77.94M	78.31M	78.67M	79.05M	79.46M	79.79M

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	4.07	20	-25	44	81	190	-176	-19	62	23	124
Net Cash From Operating Activities	-27	-28	-24	-14	-3.23	-9.71	-32	7.54	44	75	136
Net Cash From Continuing Operating Activities	-27	-28	-24	-14	-3.23	-9.71	-32	7.54	44	75	136
Net Income / (Loss) Continuing Operations	-34	-31	-31	-23	-13	-35	-76	-37	-74	24	66
Consolidated Net Income / (Loss)	-34	-31	-31	-23	-13	-35	-76	-37	-74	24	66
Depreciation Expense	2.25	3.51	3.84	3.92	4.12	7.94	20	26	27	23	21
Amortization Expense	0.05	-0.78	0.47	0.03	0.08	-	-	-	-0.47	-0.35	-3.27
Non-Cash Adjustments To Reconcile Net Income	5.79	7.05	8.22	6.18	11	16	26	34	105	47	70
Changes in Operating Assets and Liabilities, net	-1.35	-6.41	-5.44	-0.65	-5.88	1.03	-1.23	-16	-13	-19	-18
Net Cash From Investing Activities	-6.70	-4.21	-1.32	-1.87	-43	-3.84	-739	-29	15	-56	-9.21
Net Cash From Continuing Investing Activities	-6.70	-4.21	-1.32	-1.87	-43	-3.84	-739	-29	15	-56	-9.21
Purchase of Property, Plant & Equipment	-6.17	-4.21	-1.76	-1.87	-2.76	-2.84	-5.38	-8.55	-9.96	-11	-9.68
Acquisitions	0.00	-	0.00	0.00	-40	0.00	-737	0.00	0.00	5.01	0.00
Purchase of Investments	-	-	-	0.00	0.00	-1.00	0.00	-34	-20	-50	-150
Sale and/or Maturity of Investments	-	-	-	-	-	0.00	0.00	13	45	0.00	153
Other Investing Activities, net	-0.53	-	-	-	-	-	-	-	0.00	0.00	-2.85
Net Cash From Financing Activities	38	52	-0.22	59	127	204	596	3.49	2.84	4.90	-4.22
Net Cash From Continuing Financing Activities	38	52	-0.22	59	127	204	596	3.49	2.84	4.90	-4.22
Other Financing Activities, net	0.48	0.93	0.36	4.46	14	9.86	2.50	4.78	2.84	4.90	-4.22
Effect of Exchange Rate Changes	-	-	-	-	-	0.00	-1.51	-0.59	0.16	-0.42	0.72

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	11	14	-7.06	27	38	-35	-53	33	96	47	-99
Net Cash From Operating Activities	14	16	-8.97	30	30	25	5.36	34	45	53	35
Net Cash From Continuing Operating Activities	14	16	-8.97	30	30	25	5.36	34	45	53	35
Net Income / (Loss) Continuing Operations	-30	-28	-1.86	5.73	15	5.11	7.05	-0.98	19	41	29
Consolidated Net Income / (Loss)	-30	-28	-1.86	5.73	15	5.11	7.05	-0.98	19	41	29
Depreciation Expense	7.32	6.34	5.59	5.74	5.88	6.25	5.36	5.49	5.27	5.30	5.43
Amortization Expense	-	-	-	-	-	-	-0.88	-	-	-0.65	-0.61
Non-Cash Adjustments To Reconcile Net Income	44	39	10	11	8.66	17	10	29	17	14	14
Changes in Operating Assets and Liabilities, net	-7.67	-1.45	-23	6.80	0.28	-3.52	-16	0.36	6.46	-7.67	-12
Net Cash From Investing Activities	-2.80	-2.50	2.88	-2.77	-2.24	-54	-52	-0.22	48	-5.43	-128
Net Cash From Continuing Investing Activities	-2.80	-2.50	2.88	-2.77	-2.24	-54	-52	-0.22	48	-5.43	-128
Purchase of Property, Plant & Equipment	-2.80	-2.50	-2.13	-2.77	-2.24	-4.14	-1.82	-1.29	-2.79	-3.78	-2.96
Purchase of Investments	-	-	0.00	-	-	-50	-50	-50	-	-50	-125
Net Cash From Financing Activities	0.11	0.65	-0.86	-0.01	10	-4.51	-6.48	-0.57	2.98	-0.15	-6.63
Net Cash From Continuing Financing Activities	0.11	0.65	-0.86	-0.01	10	-4.51	-6.48	-0.57	2.98	-0.15	-6.63
Other Financing Activities, net	0.11	0.65	-0.86	-0.01	10	-4.51	-6.48	-0.57	2.98	-0.15	-6.63
Effect of Exchange Rate Changes	-0.18	0.30	-0.11	-0.06	0.15	-0.40	0.07	0.57	0.06	0.01	-0.06
Cash Income Taxes Paid	1.27	0.43	0.00	-	1.19	1.03	0.12	1.43	0.84	-	0.16

This table presents Veracyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	75	101	79	121	275	457	1,188	1,156	1,115	1,300	1,406
Total Current Assets	48	74	54	97	188	376	243	249	286	372	488
Cash & Equivalents	39	59	34	78	159	349	173	154	216	239	363
Short-Term Investments	-	-	-	-	-	-	3.96	25	0.00	50	50
Accounts Receivable	3.50	8.76	13	13	19	18	41	44	40	47	45
Inventories, net	3.77	3.48	5.32	3.40	6.81	4.66	11	14	16	22	21
Prepaid Expenses	1.44	2.06	2.00	2.39	2.24	3.20	13	11	13	15	10
Plant, Property, & Equipment, net	10	11	9.69	8.94	8.93	8.99	15	18	21	23	22
Total Noncurrent Assets	17	16	15	15	79	72	930	890	809	905	895
Goodwill	1.06	1.06	1.06	1.06	2.73	2.73	708	696	703	746	767
Intangible Assets	15	14	13	12	65	60	203	175	89	102	89
Other Noncurrent Operating Assets	0.16	0.13	0.33	1.09	10	9.24	18	19	16	57	39
Total Liabilities & Shareholders' Equity	75	101	79	121	275	457	1,188	1,156	1,115	1,300	1,406
Total Liabilities	24	41	41	41	36	36	91	81	71	124	96
Total Current Liabilities	15	12	12	13	17	17	64	63	61	79	60
Short-Term Debt	-	-	0.00	1.36	1.41	0.00	3.81	6.06	2.66	17	1.33
Accounts Payable	5.09	2.42	3.85	2.52	2.33	3.12	12	12	13	8.63	4.59
Accrued Expenses	8.69	9.11	8.18	9.19	14	12	39	38	38	44	49
Current Deferred Revenue	0.95	-	-	-	0.00	0.37	4.65	2.61	2.01	1.67	1.16
Other Current Liabilities	-	-	-	0.00	-	1.59	3.86	4.26	5.21	7.52	4.05
Total Noncurrent Liabilities	9.27	30	29	28	18	19	27	19	9.56	45	37
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.00	5.59	4.53	0.73	1.23	0.65
Other Noncurrent Operating Liabilities	-	-	-	0.00	18	18	21	14	8.83	44	36
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	51	60	37	80	239	421	1,097	1,075	1,044	1,176	1,310
Total Preferred & Common Equity	51	60	37	80	239	421	1,097	1,075	1,044	1,176	1,310
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	51	60	37	80	239	421	1,097	1,075	1,044	1,176	1,310
Common Stock	200	240	248	314	486	703	1,469	1,500	1,536	1,656	1,695
Retained Earnings	-149	-180	-211	-234	-247	-282	-357	-394	-468	-444	-378
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	0.00	-15	-31	-24	-36	-8.21

This table presents Veracyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,126	1,161	1,125	1,200	1,234	1,275	1,315	1,344	1,368	1,436
Total Current Assets	239	259	271	290	321	357	383	415	449	522
Cash & Equivalents	170	191	202	209	236	274	186	219	316	263
Short-Term Investments	0.00	0.00	0.00	-	-	-	101	101	51	176
Accounts Receivable	40	42	39	47	50	49	54	51	48	50
Inventories, net	14	12	16	18	19	20	24	25	20	21
Prepaid Expenses	15	14	14	16	16	14	18	18	15	12
Plant, Property, & Equipment, net	17	19	19	22	22	21	23	19	19	23
Total Noncurrent Assets	870	883	834	888	891	897	910	911	900	892
Goodwill	677	699	693	754	752	762	754	773	767	767
Intangible Assets	177	165	124	116	113	109	99	96	92	86
Other Noncurrent Operating Assets	16	19	17	17	25	25	55	40	38	39
Total Liabilities & Shareholders' Equity	1,126	1,161	1,125	1,200	1,234	1,275	1,315	1,344	1,368	1,436
Total Liabilities	78	78	71	81	102	99	120	123	110	92
Total Current Liabilities	58	58	57	58	72	70	75	76	72	56
Short-Term Debt	7.10	3.36	2.57	6.93	7.35	7.39	14	13	14	0.98
Accounts Payable	11	13	13	12	12	9.67	16	11	5.51	6.91
Accrued Expenses	32	34	35	30	43	44	36	44	48	43
Current Deferred Revenue	3.86	2.38	2.21	2.60	2.20	2.03	1.71	1.45	0.42	0.75
Other Current Liabilities	4.14	5.09	5.11	6.07	7.26	7.35	7.42	6.41	4.28	4.35
Total Noncurrent Liabilities	19	20	14	23	29	29	45	47	38	36
Noncurrent Deferred & Payable Income Tax Liabilities	4.34	4.71	3.64	1.34	1.48	1.47	1.24	1.30	1.21	0.64
Other Noncurrent Operating Liabilities	15	16	9.98	22	28	27	44	45	37	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,048	1,083	1,054	1,119	1,133	1,176	1,195	1,221	1,258	1,344
Total Preferred & Common Equity	1,048	1,083	1,054	1,119	1,133	1,176	1,195	1,221	1,258	1,344
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,048	1,083	1,054	1,119	1,133	1,176	1,195	1,221	1,258	1,344
Common Stock	1,492	1,521	1,528	1,618	1,627	1,646	1,661	1,671	1,685	1,702
Retained Earnings	-390	-410	-440	-470	-464	-449	-437	-438	-419	-349
Accumulated Other Comprehensive Income / (Loss)	-54	-28	-34	-29	-31	-21	-29	-12	-8.22	-8.22

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	29.62%	31.48%	10.55%	27.87%	30.82%	-2.40%	86.85%	35.09%	21.76%	23.46%	16.01%
EBITDA Growth	-12.48%	16.36%	14.74%	23.13%	50.84%	-221.05%	-130.14%	83.08%	-370.75%	199.55%	76.76%
EBIT Growth	-15.38%	13.93%	7.86%	20.73%	40.11%	-177.08%	-133.89%	55.39%	-110.32%	133.60%	164.92%
NOPAT Growth	-15.38%	13.93%	7.86%	16.22%	31.96%	-133.95%	-131.44%	49.84%	-108.84%	125.20%	271.40%
Net Income Growth	-14.74%	6.96%	1.13%	25.82%	45.22%	-177.08%	-116.46%	51.62%	-103.51%	132.44%	174.89%
EPS Growth	4.41%	16.15%	16.51%	31.87%	56.45%	-144.44%	-68.18%	54.05%	-100.00%	130.39%	164.52%
Operating Cash Flow Growth	2.41%	-3.77%	14.53%	43.46%	76.10%	-200.46%	-225.62%	123.83%	486.89%	69.82%	81.51%
Free Cash Flow Firm Growth	30.50%	-0.39%	25.91%	16.23%	-245.27%	75.42%	-5,867.08%	99.12%	252.12%	-571.50%	204.68%
Invested Capital Growth	48.15%	53.05%	11.21%	8.44%	169.09%	-11.71%	1,179.80%	-2.25%	-8.01%	8.74%	-0.61%
Revenue Q/Q Growth	3.87%	6.92%	1.90%	7.17%	3.42%	4.27%	17.57%	4.57%	5.22%	4.80%	4.44%
EBITDA Q/Q Growth	1.11%	12.26%	-4.54%	18.07%	-37.91%	4.76%	0.60%	52.75%	-122.90%	220.10%	61.76%
EBIT Q/Q Growth	0.32%	12.93%	-9.82%	16.59%	-26.15%	1.70%	-5.16%	24.10%	-54.52%	415.07%	119.93%
NOPAT Q/Q Growth	0.32%	12.93%	-9.82%	11.84%	-51.47%	0.35%	-5.49%	14.40%	-54.01%	191.85%	132.24%
Net Income Q/Q Growth	0.38%	10.32%	-14.97%	18.83%	-52.79%	-1.71%	-3.40%	15.46%	-48.94%	360.44%	118.86%
EPS Q/Q Growth	5.11%	12.80%	-13.75%	23.46%	-58.82%	4.35%	0.00%	10.53%	-45.71%	321.43%	110.26%
Operating Cash Flow Q/Q Growth	17.21%	-5.27%	-7.09%	25.34%	48.27%	4.63%	16.36%	20.81%	15.12%	13.57%	25.92%
Free Cash Flow Firm Q/Q Growth	5.39%	2.61%	-2.68%	-2.45%	-283.20%	77.89%	1.45%	-128.57%	254.49%	19.67%	110.54%
Invested Capital Q/Q Growth	2.89%	11.93%	5.99%	15.62%	130.62%	-9.16%	-2.50%	1.95%	-2.80%	-0.69%	-0.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.57%	60.88%	60.81%	64.05%	69.66%	64.71%	66.11%	59.24%	63.62%	66.88%	70.10%
EBITDA Margin	-62.96%	-40.05%	-30.89%	-18.57%	-6.98%	-22.95%	-28.27%	-3.54%	-13.69%	11.04%	16.70%
Operating Margin	-67.60%	-44.25%	-36.88%	-24.16%	-12.57%	-30.12%	-37.31%	-13.85%	-23.76%	3.62%	11.17%
EBIT Margin	-67.60%	-44.25%	-36.88%	-22.86%	-10.47%	-29.71%	-37.20%	-12.28%	-21.22%	5.78%	13.19%
Profit (Net Income) Margin	-68.08%	-48.18%	-43.09%	-25.00%	-10.47%	-29.71%	-34.42%	-12.33%	-20.61%	5.42%	12.83%
Tax Burden Percent	99.59%	99.36%	98.49%	100.00%	100.00%	100.00%	92.55%	100.37%	97.12%	93.76%	97.29%
Interest Burden Percent	101.13%	109.57%	118.62%	109.33%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.24%	2.71%
Return on Invested Capital (ROIC)	-170.17%	-96.95%	-69.92%	-53.38%	-18.91%	-32.23%	-11.53%	-3.15%	-6.94%	1.75%	6.24%
ROIC Less NNEP Spread (ROIC-NNEP)	-138.60%	-64.61%	-13.02%	-28.03%	-16.97%	-28.23%	-4.56%	1.34%	0.45%	-1.94%	3.28%
Return on Net Nonoperating Assets (RNNOA)	97.40%	40.36%	5.87%	14.05%	11.02%	21.66%	1.57%	-0.21%	-0.08%	0.43%	-0.90%
Return on Equity (ROE)	-72.77%	-56.59%	-64.05%	-39.32%	-7.89%	-10.57%	-9.96%	-3.37%	-7.02%	2.17%	5.34%
Cash Return on Invested Capital (CROIC)	-208.98%	-138.87%	-80.54%	-61.47%	-110.54%	-19.79%	-182.54%	-0.88%	1.41%	-6.63%	6.85%
Operating Return on Assets (OROA)	-47.78%	-32.68%	-29.54%	-21.11%	-6.37%	-9.53%	-9.93%	-3.11%	-6.75%	2.13%	5.04%
Return on Assets (ROA)	-48.12%	-35.58%	-34.50%	-23.08%	-6.37%	-9.53%	-9.19%	-3.12%	-6.55%	2.00%	4.90%
Return on Common Equity (ROCE)	-72.77%	-56.59%	-64.05%	-39.32%	-7.89%	-10.57%	-9.96%	-3.37%	-7.02%	2.17%	5.34%
Return on Equity Simple (ROE_SIMPLE)	-65.76%	-52.63%	-83.29%	-28.84%	-5.26%	-8.29%	-6.89%	-3.40%	-7.13%	2.05%	0.00%
Net Operating Profit after Tax (NOPAT)	-23	-20	-19	-16	-11	-25	-57	-29	-60	15	56
NOPAT Margin	-47.32%	-30.98%	-25.82%	-16.91%	-8.80%	-21.09%	-26.12%	-9.70%	-16.63%	3.40%	10.87%
Net Nonoperating Expense Percent (NNEP)	-31.58%	-32.34%	-56.91%	-25.35%	-1.94%	-4.00%	-6.97%	-4.49%	-7.39%	3.68%	2.97%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-2.66%	-5.74%	1.27%	4.29%
Cost of Revenue to Revenue	43.43%	39.12%	39.19%	35.95%	30.34%	35.29%	33.89%	40.76%	36.38%	33.12%	29.90%
SG&A Expenses to Revenue	45.62%	36.55%	32.09%	26.04%	24.12%	31.26%	46.17%	24.69%	23.88%	24.81%	21.42%
R&D to Revenue	25.85%	23.54%	19.29%	16.11%	12.34%	14.64%	13.60%	13.69%	15.87%	15.55%	13.69%
Operating Expenses to Revenue	124.18%	105.13%	97.70%	88.21%	82.22%	94.84%	103.42%	79.60%	92.49%	65.85%	60.99%
Earnings before Interest and Taxes (EBIT)	-33	-29	-27	-21	-13	-35	-82	-36	-77	26	68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-31	-26	-22	-17	-8.40	-27	-62	-10	-49	49	86
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.89	3.63	5.97	6.39	5.69	6.73	2.67	1.58	1.92	2.61	2.54
Price to Tangible Book Value (P/TBV)	5.69	4.87	9.62	7.65	7.94	7.90	15.75	8.33	7.96	9.36	7.34
Price to Revenue (P/Rev)	4.02	3.32	3.09	5.54	11.33	24.12	13.33	5.74	5.57	6.88	6.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	127.14	50.16
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.79%	1.99%
Enterprise Value to Invested Capital (EV/IC)	10.04	7.26	7.64	15.20	14.78	34.48	2.99	1.70	2.16	3.10	3.25
Enterprise Value to Revenue (EV/Rev)	3.33	2.80	2.97	5.01	10.02	21.15	12.54	5.16	4.97	6.27	5.64
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	56.84	33.78
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	108.63	42.76
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	184.77	51.88
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	203.04	40.60	37.24	21.40
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	147.49	0.00	47.27
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.43	0.68	0.37	0.01	0.00	0.00	0.01	0.00	0.01	0.00
Long-Term Debt to Equity	0.10	0.43	0.68	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.70	-0.62	-0.45	-0.50	-0.65	-0.77	-0.34	-0.16	-0.18	-0.22	-0.28
Leverage Ratio	1.51	1.59	1.86	1.70	1.24	1.11	1.08	1.08	1.07	1.09	1.09
Compound Leverage Factor	1.53	1.74	2.20	1.86	1.24	1.11	1.08	1.08	1.07	1.09	1.09
Debt to Total Capital	8.87%	29.99%	40.41%	26.79%	0.87%	0.19%	0.35%	0.56%	0.25%	1.42%	0.10%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	1.25%	0.58%	0.00%	0.35%	0.56%	0.25%	1.42%	0.10%
Long-Term Debt to Total Capital	8.87%	29.99%	40.41%	25.54%	0.29%	0.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.13%	70.01%	59.59%	73.21%	99.13%	99.81%	99.65%	99.44%	99.75%	98.58%	99.90%
Debt to EBITDA	-0.16	-0.98	-1.14	-1.71	-0.25	-0.03	-0.06	-0.58	-0.05	0.35	0.02
Net Debt to EBITDA	1.10	1.30	0.39	2.86	18.72	12.93	2.79	16.46	4.33	-5.54	-4.77
Long-Term Debt to EBITDA	-0.16	-0.98	-1.14	-1.63	-0.08	-0.03	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.21	-1.27	-1.36	-1.88	-0.20	-0.03	-0.07	-0.21	-0.04	1.12	0.02
Net Debt to NOPAT	1.46	1.68	0.47	3.14	14.85	14.07	3.02	6.01	3.56	-18.00	-7.32
Long-Term Debt to NOPAT	-0.21	-1.27	-1.36	-1.79	-0.07	-0.03	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.93	1.08	-0.10	5.79	22.66	47.40	18.95	12.45	16.78	15.04	21.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.25	6.38	4.48	7.42	10.74	22.39	3.79	3.97	4.66	4.73	8.15
Quick Ratio	2.89	5.89	3.87	6.98	10.23	21.92	3.41	3.56	4.19	4.27	7.63
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-29	-29	-21	-18	-62	-15	-908	-8.00	12	-57	62
Operating Cash Flow to CapEx	-437.39%	-664.66%	-1,818.63%	-721.50%	-118.26%	-342.30%	-588.19%	88.14%	443.95%	665.33%	1,408.57%
Free Cash Flow to Firm to Interest Expense	-76.11	-10.48	-4.33	-9.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-71.34	-10.15	-4.84	-6.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-87.65	-11.68	-5.11	-7.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.71	0.74	0.80	0.92	0.61	0.32	0.27	0.25	0.32	0.37	0.38
Accounts Receivable Turnover	15.11	10.62	6.70	7.11	7.41	6.22	7.33	6.94	8.56	10.26	11.34
Inventory Turnover	5.76	7.03	6.41	7.58	7.16	7.23	9.37	9.47	8.64	7.79	7.31
Fixed Asset Turnover	6.84	5.97	6.80	9.88	13.47	13.11	18.23	18.08	18.86	20.48	22.91
Accounts Payable Turnover	3.44	6.78	8.98	10.39	15.08	15.23	9.61	9.96	10.57	13.68	23.38
Days Sales Outstanding (DSO)	24.16	34.37	54.46	51.34	49.27	58.70	49.82	52.61	42.66	35.58	32.18
Days Inventory Outstanding (DIO)	63.36	51.91	56.95	48.14	51.01	50.46	38.96	38.54	42.26	46.83	49.92
Days Payable Outstanding (DPO)	105.97	53.82	40.63	35.14	24.20	23.97	37.96	36.65	34.53	26.68	15.61
Cash Conversion Cycle (CCC)	-18.45	32.46	70.79	64.35	76.07	85.20	50.81	54.49	50.40	55.73	66.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	25	28	30	82	72	922	902	829	902	898
Invested Capital Turnover	3.60	3.13	2.71	3.16	2.15	1.53	0.44	0.33	0.42	0.51	0.57
Increase / (Decrease) in Invested Capital	5.34	8.72	2.82	2.36	51	-9.56	850	-21	-72	73	-5.49
Enterprise Value (EV)	165	183	214	461	1,206	2,485	2,754	1,530	1,796	2,797	2,916
Market Capitalization	199	216	222	510	1,364	2,833	2,927	1,703	2,009	3,069	3,328
Book Value per Share	$1.85	$2.13	$1.09	$1.97	$4.90	$7.28	$15.43	$14.98	$14.30	$15.17	$16.57
Tangible Book Value per Share	$1.26	$1.59	$0.68	$1.65	$3.52	$6.19	$2.62	$2.85	$3.46	$4.23	$5.73
Total Capital	56	85	62	109	242	422	1,100	1,081	1,047	1,193	1,311
Total Debt	4.99	26	25	29	2.10	0.81	3.81	6.06	2.66	17	1.33
Total Long-Term Debt	4.99	26	25	28	0.69	0.81	0.00	0.00	0.00	0.00	0.00
Net Debt	-34	-34	-8.65	-49	-157	-349	-173	-173	-214	-272	-412
Capital Expenditures (CapEx)	6.17	4.21	1.32	1.87	2.73	2.84	5.38	8.55	9.96	11	9.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.01	2.75	8.01	7.26	12	9.53	5.60	13	11	21	17
Debt-free Net Working Capital (DFNWC)	33	62	42	85	172	359	183	192	227	311	430
Net Working Capital (NWC)	33	62	42	84	170	359	179	186	224	294	428
Net Nonoperating Expense (NNE)	10	11	12	7.44	2.01	10	18	7.80	14	-9.00	-10
Net Nonoperating Obligations (NNO)	-35	-34	-9.25	-49	-158	-349	-174	-174	-215	-274	-412
Total Depreciation and Amortization (D&A)	2.30	2.74	4.31	3.95	4.20	7.94	20	26	27	23	18
Debt-free, Cash-free Net Working Capital to Revenue	-12.14%	4.23%	11.13%	7.89%	10.23%	8.12%	2.55%	4.46%	2.93%	4.75%	3.26%
Debt-free Net Working Capital to Revenue	67.05%	95.40%	58.23%	92.66%	142.58%	305.49%	83.26%	64.78%	62.88%	69.68%	83.10%
Net Working Capital to Revenue	67.05%	95.40%	58.23%	91.18%	141.41%	305.49%	81.52%	62.73%	62.15%	65.87%	82.85%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.30)	($1.09)	($0.91)	($0.62)	($0.27)	($0.66)	($1.11)	($0.51)	($1.02)	$0.32	$0.84
Adjusted Weighted Average Basic Shares Outstanding	27.85M	33.85M	34.29M	41.11M	49.74M	67.00M	67.89M	71.55M	72.64M	76.48M	78.58M
Adjusted Diluted Earnings per Share	($1.30)	($1.09)	($0.91)	($0.62)	($0.27)	($0.66)	($1.11)	($0.51)	($1.02)	$0.31	$0.82
Adjusted Weighted Average Diluted Shares Outstanding	27.85M	33.85M	34.29M	41.11M	49.74M	67.00M	67.89M	71.55M	72.64M	78.16M	80.57M
Adjusted Basic & Diluted Earnings per Share	($1.30)	($1.09)	($0.91)	($0.62)	($0.27)	($0.66)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.99M	28.83M	33.93M	37.02M	46.14M	53.24M	71.22M	72.15M	75.07M	77.94M	79.46M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-20	-19	-16	-11	-25	-57	-26	-12	18	76
Normalized NOPAT Margin	-47.32%	-30.98%	-25.82%	-16.91%	-8.80%	-21.09%	-26.12%	-8.91%	-3.38%	4.10%	14.73%
Pre Tax Income Margin	-68.37%	-48.49%	-43.75%	-25.00%	-10.47%	-29.71%	-37.20%	-12.28%	-21.22%	5.78%	13.19%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-88.53	-10.45	-5.37	-10.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-61.97	-7.31	-3.76	-7.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-104.84	-11.97	-5.64	-11.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-78.28	-8.84	-4.03	-8.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	79,458,427.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	79,458,427.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.36
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.20%	22.29%	17.50%	26.69%	28.58%	20.81%	18.20%	13.75%	13.82%	18.55%	21.49%
EBITDA Growth	-780.01%	-874.83%	359.11%	1,023.77%	201.23%	140.17%	247.37%	-48.55%	6.29%	384.70%	192.16%
EBIT Growth	-235.46%	-785.56%	76.42%	188.93%	156.59%	111.30%	489.31%	-83.02%	12.11%	1,080.19%	303.53%
NOPAT Growth	-227.88%	-555.11%	55.65%	163.66%	148.65%	124.95%	184.53%	15.11%	115.06%	507.52%	687.24%
Net Income Growth	-239.54%	-636.03%	76.96%	168.25%	151.17%	118.07%	478.06%	-117.09%	26.28%	704.79%	307.36%
EPS Growth	-241.67%	-533.33%	81.82%	158.33%	146.34%	118.42%	550.00%	-114.29%	26.32%	614.29%	288.89%
Operating Cash Flow Growth	101.69%	59.61%	-312.80%	77.40%	111.44%	57.69%	159.80%	13.63%	49.37%	114.41%	556.75%
Free Cash Flow Firm Growth	-83.77%	179.33%	-205.66%	-199.82%	-596.30%	-240.02%	90.92%	99.43%	164.19%	163.58%	1,700.43%
Invested Capital Growth	-3.52%	-8.01%	2.38%	0.00%	6.44%	8.74%	0.54%	1.02%	-0.56%	-0.61%	-1.52%
Revenue Q/Q Growth	-0.24%	8.98%	-1.38%	18.16%	1.25%	2.39%	-3.51%	13.71%	1.31%	6.65%	-1.11%
EBITDA Q/Q Growth	-1,483.15%	-7.51%	115.26%	255.76%	73.49%	-57.34%	31.91%	-47.31%	258.44%	87.46%	-23.17%
EBIT Q/Q Growth	-259.70%	-2.35%	93.74%	485.80%	128.88%	-79.56%	115.74%	-83.17%	1,411.12%	115.12%	-26.23%
NOPAT Q/Q Growth	-294.22%	-11.87%	86.89%	210.09%	201.27%	-42.64%	-55.56%	49.91%	462.87%	62.03%	-42.42%
Net Income Q/Q Growth	-252.51%	4.47%	93.41%	407.62%	164.30%	-66.26%	37.83%	-113.91%	2,052.76%	115.02%	-30.24%
EPS Q/Q Growth	-241.67%	7.32%	94.74%	450.00%	171.43%	-63.16%	28.57%	-111.11%	2,500.00%	108.33%	-30.00%
Operating Cash Flow Q/Q Growth	-15.00%	9.75%	-157.65%	429.86%	1.31%	-18.15%	-78.14%	526.73%	33.19%	17.49%	-33.03%
Free Cash Flow Firm Q/Q Growth	-99.01%	432.38%	-151.77%	-3,566.61%	95.09%	-50.20%	96.64%	-128.95%	655.75%	52.23%	-17.37%
Invested Capital Q/Q Growth	0.00%	-2.80%	10.35%	-1.36%	0.60%	-0.69%	2.03%	-0.89%	-0.98%	-0.57%	0.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	64.02%	61.08%	67.51%	68.09%	68.19%	63.93%	69.46%	68.97%	69.22%	72.51%	72.74%
EBITDA Margin	-24.91%	-24.58%	3.80%	11.45%	19.62%	8.17%	11.17%	5.18%	18.32%	32.20%	25.02%
Operating Margin	-35.22%	-36.16%	-4.81%	4.03%	10.37%	3.52%	2.54%	-4.05%	17.40%	26.45%	16.28%
EBIT Margin	-33.04%	-31.03%	-1.97%	6.43%	14.54%	2.90%	6.49%	0.96%	14.32%	28.89%	21.55%
Profit (Net Income) Margin	-32.87%	-28.81%	-1.92%	5.01%	13.08%	4.31%	6.16%	-0.75%	14.51%	29.26%	20.64%
Tax Burden Percent	99.48%	92.85%	97.69%	77.90%	89.95%	148.50%	94.87%	-78.40%	101.31%	101.27%	95.77%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	22.10%	10.05%	-48.50%	5.13%	178.40%	-1.31%	-1.27%	4.23%
Return on Invested Capital (ROIC)	-9.74%	-10.56%	-1.40%	2.78%	4.51%	2.69%	1.22%	1.68%	9.64%	15.38%	9.25%
ROIC Less NNEP Spread (ROIC-NNEP)	-5.68%	-8.79%	-2.11%	0.91%	2.65%	3.14%	-0.58%	3.57%	10.96%	14.36%	7.28%
Return on Net Nonoperating Assets (RNNOA)	0.98%	1.61%	0.38%	-0.18%	-0.56%	-0.69%	0.12%	-0.82%	-2.80%	-3.95%	-2.04%
Return on Equity (ROE)	-8.75%	-8.95%	-1.02%	2.59%	3.95%	2.00%	1.34%	0.86%	6.84%	11.43%	7.21%
Cash Return on Invested Capital (CROIC)	-0.91%	1.41%	-8.54%	-210.44%	-8.11%	-6.63%	1.89%	0.37%	3.24%	6.85%	9.76%
Operating Return on Assets (OROA)	-10.07%	-9.87%	-0.63%	2.08%	5.15%	1.07%	2.39%	0.36%	5.37%	11.04%	8.49%
Return on Assets (ROA)	-10.02%	-9.16%	-0.61%	1.62%	4.64%	1.59%	2.27%	-0.28%	5.44%	11.18%	8.13%
Return on Common Equity (ROCE)	-8.75%	-8.95%	-1.02%	2.59%	3.95%	2.00%	1.34%	0.86%	6.84%	11.43%	7.21%
Return on Equity Simple (ROE_SIMPLE)	-4.74%	0.00%	-6.09%	-4.77%	-0.79%	0.00%	2.77%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-25	-3.26	3.59	11	6.20	2.76	4.13	23	38	22
NOPAT Margin	-24.66%	-25.31%	-3.37%	3.14%	9.33%	5.23%	2.41%	3.17%	17.63%	26.78%	15.60%
Net Nonoperating Expense Percent (NNEP)	-4.06%	-1.77%	0.71%	1.87%	1.86%	-0.44%	1.80%	-1.90%	-1.32%	1.02%	1.97%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.37%	-	-	-	0.52%	0.23%	0.33%	1.83%	2.87%	1.61%
Cost of Revenue to Revenue	35.98%	38.92%	32.49%	31.91%	31.81%	36.07%	30.54%	31.03%	30.78%	27.49%	27.26%
SG&A Expenses to Revenue	18.13%	24.23%	27.06%	27.74%	22.22%	22.69%	29.53%	24.84%	20.69%	12.35%	17.03%
R&D to Revenue	14.78%	19.02%	16.49%	14.39%	15.17%	16.26%	15.48%	12.50%	12.12%	14.82%	19.49%
Operating Expenses to Revenue	104.58%	106.24%	72.32%	66.61%	60.34%	65.24%	69.18%	75.06%	53.87%	47.99%	58.40%
Earnings before Interest and Taxes (EBIT)	-30	-30	-1.91	7.36	17	3.44	7.43	1.25	19	41	30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-24	3.68	13	23	9.70	13	6.74	24	45	35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.54	1.92	1.49	1.46	2.22	2.61	1.93	1.73	2.15	2.54	1.90
Price to Tangible Book Value (P/TBV)	6.85	7.96	6.70	6.18	8.57	9.36	6.77	6.01	6.79	7.34	5.21
Price to Revenue (P/Rev)	4.73	5.57	4.43	4.15	6.15	6.88	4.99	4.42	5.45	6.44	4.72
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	127.14	69.93	80.38	89.09	50.16	29.08
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.79%	1.43%	1.24%	1.12%	1.99%	3.44%
Enterprise Value to Invested Capital (EV/IC)	1.67	2.16	1.60	1.58	2.59	3.10	2.21	1.98	2.60	3.25	2.34
Enterprise Value to Revenue (EV/Rev)	4.15	4.97	3.89	3.57	5.52	6.27	4.40	3.78	4.74	5.64	3.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	152.76	56.84	34.95	34.83	43.99	33.78	19.42
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	108.63	58.10	62.46	75.72	42.76	23.38
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	184.77	91.27	143.95	97.01	51.88	28.21
Enterprise Value to Operating Cash Flow (EV/OCF)	37.09	40.60	39.04	28.37	35.51	37.24	22.79	19.36	21.69	21.40	12.77
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	147.49	0.00	0.00	0.00	0.00	117.49	541.83	80.12	47.27	23.79
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.17	-0.18	-0.18	-0.20	-0.21	-0.22	-0.21	-0.23	-0.26	-0.28	-0.28
Leverage Ratio	1.07	1.07	1.07	1.09	1.08	1.09	1.09	1.10	1.09	1.09	1.08
Compound Leverage Factor	1.07	1.07	1.07	1.09	1.08	1.09	1.09	1.10	1.09	1.09	1.08
Debt to Total Capital	0.24%	0.25%	0.62%	0.64%	0.62%	1.42%	1.19%	1.09%	1.07%	0.10%	0.07%
Short-Term Debt to Total Capital	0.24%	0.25%	0.62%	0.64%	0.62%	1.42%	1.19%	1.09%	1.07%	0.10%	0.07%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.76%	99.75%	99.38%	99.36%	99.38%	98.58%	98.81%	98.91%	98.93%	99.90%	99.93%
Debt to EBITDA	-0.12	-0.05	-0.16	-0.25	0.48	0.35	0.25	0.26	0.25	0.02	0.01
Net Debt to EBITDA	9.02	4.33	4.56	7.67	-17.35	-5.54	-4.68	-5.92	-6.61	-4.77	-4.01
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.07	-0.04	-0.12	-0.16	-0.45	1.12	0.64	1.07	0.56	0.02	0.01
Net Debt to NOPAT	5.13	3.56	3.61	4.85	16.18	-18.00	-12.23	-24.45	-14.58	-7.32	-5.83
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.65	16.91	12.25	9.82	16.00	14.99	11.70	10.53	15.03	21.16	17.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.74	4.66	5.00	4.44	5.08	4.73	5.10	5.43	6.23	8.15	9.31
Quick Ratio	4.22	4.19	4.41	3.96	4.59	4.27	4.54	4.86	5.74	7.63	8.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	8.90	47	-25	-899	-44	-66	-2.23	-5.10	28	43	36
Operating Cash Flow to CapEx	505.75%	622.83%	-420.15%	1,067.69%	1,336.44%	592.22%	294.78%	2,613.14%	1,603.04%	1,391.08%	1,188.89%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.32	0.32	0.32	0.35	0.37	0.37	0.37	0.37	0.38	0.39
Accounts Receivable Turnover	8.65	8.56	8.43	7.94	9.66	10.26	9.23	9.48	10.25	11.34	10.43
Inventory Turnover	8.08	8.64	7.90	6.24	6.87	7.79	6.96	6.87	7.66	7.31	6.90
Fixed Asset Turnover	18.79	18.86	18.74	17.93	21.01	20.48	21.02	23.46	24.70	22.91	23.98
Accounts Payable Turnover	10.15	10.57	9.43	9.94	11.22	13.68	10.64	12.93	20.53	23.38	13.93
Days Sales Outstanding (DSO)	42.21	42.66	43.27	45.95	37.80	35.58	39.56	38.52	35.62	32.18	35.00
Days Inventory Outstanding (DIO)	45.15	42.26	46.19	58.50	53.11	46.83	52.43	53.13	47.66	49.92	52.90
Days Payable Outstanding (DPO)	35.97	34.53	38.69	36.71	32.52	26.68	34.31	28.24	17.78	15.61	26.20
Cash Conversion Cycle (CCC)	51.40	50.40	50.77	67.74	58.39	55.73	57.69	63.41	65.50	66.49	61.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	853	829	915	903	908	902	920	912	903	898	906
Invested Capital Turnover	0.39	0.42	0.42	0.89	0.48	0.51	0.50	0.53	0.55	0.57	0.59
Increase / (Decrease) in Invested Capital	-31	-72	21	903	55	73	4.98	9.23	-5.10	-5.49	-14
Enterprise Value (EV)	1,425	1,796	1,461	1,428	2,348	2,797	2,038	1,810	2,348	2,916	2,121
Market Capitalization	1,625	2,009	1,664	1,657	2,615	3,069	2,311	2,117	2,701	3,328	2,559
Book Value per Share	$14.49	$14.30	$14.90	$14.81	$15.31	$15.17	$15.33	$15.59	$15.99	$16.57	$16.92
Tangible Book Value per Share	$3.26	$3.46	$3.31	$3.50	$3.97	$4.23	$4.38	$4.49	$5.06	$5.73	$6.18
Total Capital	1,057	1,047	1,126	1,140	1,183	1,193	1,209	1,234	1,271	1,311	1,345
Total Debt	2.57	2.66	6.93	7.35	7.39	17	14	13	14	1.33	0.98
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-200	-214	-202	-229	-267	-272	-273	-307	-353	-412	-438
Capital Expenditures (CapEx)	2.80	2.50	2.13	2.77	2.24	4.14	1.82	1.29	2.79	3.78	2.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	14	11	30	20	20	21	35	31	24	17	28
Debt-free Net Working Capital (DFNWC)	216	227	239	256	294	311	322	352	391	430	467
Net Working Capital (NWC)	214	224	232	249	287	294	308	338	377	428	466
Net Nonoperating Expense (NNE)	7.40	3.44	-1.40	-2.15	-4.35	1.09	-4.29	5.11	4.11	-3.48	-7.02
Net Nonoperating Obligations (NNO)	-201	-215	-203	-230	-268	-274	-275	-309	-354	-412	-438
Total Depreciation and Amortization (D&A)	7.32	6.34	5.59	5.74	5.88	6.25	5.36	5.49	5.27	4.65	4.82
Debt-free, Cash-free Net Working Capital to Revenue	4.08%	2.93%	8.02%	5.06%	4.67%	4.75%	7.56%	6.46%	4.89%	3.26%	5.17%
Debt-free Net Working Capital to Revenue	63.09%	62.88%	63.73%	64.10%	69.11%	69.68%	69.57%	73.40%	78.90%	83.10%	86.21%
Net Working Capital to Revenue	62.34%	62.15%	61.89%	62.26%	67.37%	65.87%	66.47%	70.60%	76.15%	82.85%	86.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.41)	($0.38)	($0.02)	$0.07	$0.20	$0.07	$0.09	($0.01)	$0.24	$0.52	$0.36
Adjusted Weighted Average Basic Shares Outstanding	72.80M	72.64M	74.76M	76.54M	77.01M	76.48M	78.03M	78.39M	78.73M	78.58M	79.54M
Adjusted Diluted Earnings per Share	($0.41)	($0.38)	($0.02)	$0.07	$0.19	$0.07	$0.09	($0.01)	$0.24	$0.50	$0.35
Adjusted Weighted Average Diluted Shares Outstanding	72.80M	72.64M	74.76M	77.16M	78.46M	78.16M	80.06M	78.39M	79.69M	80.57M	81.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	73.04M	75.07M	76.45M	76.81M	77.50M	77.94M	78.31M	78.67M	79.05M	79.46M	79.79M
Normalized Net Operating Profit after Tax (NOPAT)	2.21	-2.43	-2.96	3.59	11	4.85	2.76	11	16	26	22
Normalized NOPAT Margin	2.46%	-2.47%	-3.06%	3.14%	9.47%	4.09%	2.41%	8.19%	12.18%	18.51%	15.60%
Pre Tax Income Margin	-33.04%	-31.03%	-1.97%	6.43%	14.54%	2.90%	6.49%	0.96%	14.32%	28.89%	21.55%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Veracyte's quarterly statements over the last four years, focusing on trends in revenue, profitability, cash flow, and the balance sheet.

In Q4 2025, operating revenue reached about 140.6 million with net income from continuing operations of 41.15 million, marking a strong quarterly profitability inflection.
Net cash from continuing operating activities in Q4 2025 was about 52.6 million, signaling robust cash generation from core operations.
Gross margin in Q4 2025 was roughly 72.4% (gross profit 101.97 million on 140.6 million in revenue), indicating favorable product economics at the period end.
Throughout 2025, revenue trended higher each quarter: Q1 about 114.5 million, Q2 about 130.2 million, Q3 about 131.9 million, and Q4 about 140.6 million, showing steady top-line growth within the year.
Earnings per share improved meaningfully in Q4 2025, with diluted EPS around 0.50 (basic 0.52), after a more modest outlook earlier in the year, reflecting improved profitability per share.
The balance sheet shows a strong liquidity and equity base, with total assets near 1.37 billion and total equity around 1.20+ billion by late 2025, supporting ongoing operations and potential investments.
R&D expense remained meaningful (about 20.9 million in Q4 2025) as Veracyte continues to invest in its pipeline, a typical feature of a growth-focused biotech/minimally invasive diagnostics company.
Cash and cash equivalents remained substantial (roughly 315 million in late-2025 quarters), providing a solid liquidity cushion for timing and execution of strategic initiatives.
Historically, Veracyte posted meaningful net losses in multiple quarters across 2022–2024; while 2025 shows improvement, the four-year trail includes periods of negative profitability that investors should weigh against the latest results.

05/14/26 04:44 PM ETAI Generated. May Contain Errors.

Veracyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Veracyte's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Veracyte's net income appears to be on a downward trend, with a most recent value of $66.35 million in 2025, falling from -$33.70 million in 2015. The previous period was $24.14 million in 2024. See where experts think Veracyte is headed by visiting Veracyte's forecast page.

Veracyte's total operating income in 2025 was $57.78 million, based on the following breakdown:

Total Gross Profit: $362.53 million
Total Operating Expenses: $315.42 million

Over the last 10 years, Veracyte's total revenue changed from $49.50 million in 2015 to $517.15 million in 2025, a change of 944.7%.

Veracyte's total liabilities were at $96.44 million at the end of 2025, a 22.3% decrease from 2024, and a 301.9% increase since 2015.

In the past 10 years, Veracyte's cash and equivalents has ranged from $33.89 million in 2017 to $362.58 million in 2025, and is currently $362.58 million as of their latest financial filing in 2025.

Over the last 10 years, Veracyte's book value per share changed from 1.85 in 2015 to 16.57 in 2025, a change of 794.2%.

Related Companies

Financial statements for NASDAQ:VCYT last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Financials

Financials Breakdown Chart

Key Financial Trends

Veracyte Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Financials

Annual Income Statements for Veracyte

Quarterly Income Statements for Veracyte

Annual Cash Flow Statements for Veracyte

Quarterly Cash Flow Statements for Veracyte

Annual Balance Sheets for Veracyte

Quarterly Balance Sheets for Veracyte

Annual Metrics And Ratios for Veracyte

Quarterly Metrics And Ratios for Veracyte

Financials Breakdown Chart

Key Financial Trends

Veracyte Financials - Frequently Asked Questions

When does Veracyte's financial year end?

How has Veracyte's net income changed over the last 10 years?

What is Veracyte's operating income?

How has Veracyte's revenue changed over the last 10 years?

How much debt does Veracyte have?

How much cash does Veracyte have?

How has Veracyte's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools